WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a number one late clinical-stage mobile therapeutics firm centered on persistent kidney illness (CKD), as we speak introduced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will current a company overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.
Access to the dwell webcast will probably be accessible on the Events and Presentations part of ProKidney’s investor relations web site at https://investors.prokidney.com/news-events/events-and-presentations.
Investors attending the convention and curious about assembly with ProKidney administration could request a gathering by contacting their Jefferies consultant.
About ProKidney
ProKidney, a pioneer in the therapy of CKD via improvements in mobile remedy, was based in 2015 after a decade of analysis. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous mobile remedy with the potential to not solely gradual and stabilize the development of CKD, however in some circumstances presumably drive significant enchancment in kidney perform. Late-stage CKD, Stage 3b – 4, is a key goal for REACT™ remedy. REACT™ has acquired Regenerative Medicine Advanced Therapy (RMAT) designation, in addition to FDA and EMA steering, supporting its ongoing Phase 3 scientific program, which launched in January 2022. For extra data, go to www.prokidney.com.
About CKD
There aren’t any therapies that successfully reverse late-stage CKD. CKD is a critical analysis with vital morbidity and mortality, notable for the 5-year mortality of a brand new analysis of CKD Stage 4 being increased than that of a brand new non-metastatic most cancers analysis. CKD most frequently presents as a progressive decline in kidney perform finally leading to the failure of the kidneys and the want for renal alternative remedy, reminiscent of hemodialysis, or kidney transplant. One in three Americans is at threat for CKD which at the moment impacts roughly 75 million individuals in the United States and Europe and over 400 million throughout Asia. CKD is amongst the largest single bills incurred by the US Health care system.
Forward-Looking Statements
This press launch contains “forward-looking statements” inside the which means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s precise outcomes could differ from its expectations, estimates and projections and consequently, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Words reminiscent of “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and related expressions (or the detrimental variations of such phrases or expressions) are meant to establish such forward-looking statements. These forward-looking statements embrace, with out limitation, the mixed firm’s expectations with respect to monetary outcomes, future efficiency, growth and commercialization of merchandise, if authorized, the potential advantages and influence of the mixed firm’s merchandise, if authorized, potential regulatory approvals, anticipated monetary impacts and different results of the business mixture on the mixed firm’s business, and the measurement and potential development of present or future markets for the mixed firm’s merchandise, if authorized. Most of those elements are exterior of the mixed firm’s management and are troublesome to predict. Factors which will trigger such variations embrace, however are usually not restricted to: the lack of ability to keep the itemizing of the mixed firm’s Class A abnormal shares on the Nasdaq following the business mixture; the lack of ability to implement business plans, forecasts, and different expectations and to acknowledge the anticipated advantages of the business mixture or establish and notice further alternatives, which can be affected by, amongst different issues, competitors and the skill of the mixed firm to develop and handle development profitably and retain its key staff; the threat of downturns and a altering regulatory panorama in the extremely aggressive biotechnology trade; the lack of ability of the mixed firm to elevate financing in the future; the lack of ability of the mixed firm to receive and keep regulatory clearance or approval for its merchandise, and any associated restrictions and limitations of any cleared or authorized product; the lack of ability of the mixed firm to establish, in-license or purchase further know-how; the lack of ability of mixed firm to compete with different corporations at the moment advertising and marketing or engaged in the biologics market and in the space of therapy of kidney illnesses; the measurement and development potential of the markets for the mixed firm’s merchandise, if authorized, and its skill to serve these markets, both alone or in partnership with others; the mixed firm’s estimates concerning bills, future income, capital necessities and wants for added financing; the mixed firm’s monetary efficiency; the mixed firm’s mental property rights; uncertainties inherent in cell remedy analysis and growth, together with the precise time it takes to provoke and full scientific research and the timing and content material of selections made by regulatory authorities; the influence of COVID-19 or geo-political battle reminiscent of the struggle in Ukraine on the mixed firm’s business; and different dangers and uncertainties indicated from time to time in the proxy assertion relating to the business mixture, together with these underneath “Risk Factors” therein, and in the mixed firm’s different filings with the Securities and Exchange Commission. The mixed firm cautions readers that the foregoing listing of things just isn’t unique and cautions readers not to place undue reliance upon any forward-looking statements, which communicate solely as of the date made. The mixed firm doesn’t undertake or settle for any obligation or endeavor to launch publicly any updates or revisions to any forward-looking statements to replicate any change in its expectations or any change in occasions, circumstances or circumstances on which any such assertion is predicated.
Contact Information
ProKidney Corp.
Investors & Media
Glenn Schulman, PharmD, MPH
SVP, Investor Relations
[email protected]
